Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonazepam crossover trial in ARID1B-related intellectual disability
NL-OMON52899Phase 4Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of clonazepam in ARID1B-related intellectual disability (ARID1B-ID) and intellectual disability (ID) (3 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Maximum serum concentration, Time to maximum serum concentration and 23 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
clonazepam
03
Conditions
ARID1B-related intellectual disability (ARID1B-ID)intellectual disability (ID)
Beyond the preview
Go deeper on NL-OMON52899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52899.